A Guide to Investigating Aflibercept Sequence Patents

The "A Guide to Investigating Aflibercept Sequence Patents" provides an in-depth analysis of global Aflibercept sequence patents through detailed research. The guide consists of five sections: Preface, Introduction to Aflibercept, Practical Patent Search, Patent Analysis, and Conclusion. It aims to instruct readers on using the Bio database for drug sequence patent search and analysis. In August 2023, Regeneron Pharmaceuticals announced FDA approval for an 8 mg injection of Eylea (Aflibercept) for wAMD, DME, and DR, extending the injection interval from two months to four months. Initially approved in 2011, Eylea was developed by Regeneron and Bayer. Aflibercept is a fully human recombinant fusion protein that inhibits angiogenesis and vascular permeability by binding VEGF-A, VEGF-B, and PlGF. Its indications include ophthalmic diseases and metastatic colorectal cancer. To aid biomedical researchers in understanding Aflibercept's global development and IP protection, the guide leverages the Patsnap Bio sequence database. It covers practical aspects of sequence patent searches, including retrieval methods and analytical techniques. The guide further analyzes the global status and core patents of Aflibercept, providing comprehensive insights on its patent landscape.